Macfarlanes advises Caledonia Investments on sale of stake in BioAgilytix to Cinven and subsequent re-investment

15 December 2021

Macfarlanes has advised listed investment trust Caledonia Investments on the sale of its stake in BioAgilytix, a US-based pharmaceuticals services business, for $183m (net of fees) as part of the investment into the business by private equity firm Cinven.

Caledonia have re-invested $42m from the proceeds back into BioAgilytix, alongside current majority investor Cobepa and a consortium of other sponsors.

The Macfarlanes team was led by corporate and M&A partner Stephen Drewitt alongside senior solicitor Nicholas Page.